Mukesh Ambani, chairman of Reliance Industries, is now going to enter the business of genetic mapping. Reliance Industries will try to make the healthcare trend more affordable and accessible to more and more people in India’s growing consumer market led by American startups like 23andMe.
Claim to be the cheapest
According to a report published in Bloomberg, Ramesh Hariharan, CEO of Strand Life Sciences Pvt Ltd, which manufactures the products, says that within a few weeks, it will start the genome sequencing test for Rs 12,000. Reliance Industries acquired the Bangalore-based firm in 2021 and now holds around 80% stake in it.
He explained that genome testing, which is currently about 86% cheaper than other locally available facilities, can identify a person’s cancer, heart and neuro-degenerative diseases, as well as genetic diseases passed down through many lineages. can reveal its trends for
Wealth of biological data
India, which is the world’s largest populated country, can create a wealth of biological data from it, which can play a big role in making medicines and preventing disease in this area. It also dovetails with Mukesh Ambani’s ambitions to move into the world of data – he has often referred to it as the ‘new oil’.
Testing cost of other companies
While 23andMe Ancestry Report can be purchased for $99, its Health Plus Ancestry Report costs $199. While full genome sequencing from MapmyGenome and Medgenome costs more than $1,000. Some companies in China also offer the service for 599 yuan ($87), but it doesn’t cover all the diseases that Strand does.
